Deric Savior, MD, Promoted to Head of ...

Dr. Deric C. Savior

Claim this profile

Paoli Memorial Hospital

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
27 drugs studied

Area of expertise

1

Lung Cancer

Deric C. Savior has run 5 trials for Lung Cancer. Some of their research focus areas include:

Stage III
Stage II
Stage I
2

Non-Small Cell Lung Cancer

Deric C. Savior has run 4 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage III
Stage II
Stage IV

Affiliated Hospitals

Image of trial facility.

Paoli Memorial Hospital

Image of trial facility.

Lankenau Medical Center

Clinical Trials Deric C. Savior is currently running

Image of trial facility.

Chemotherapy + Radiation Therapy

for Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.

Recruiting

1 award

Phase 2 & 3

21 criteria

Image of trial facility.

Relugolix + Radiation

for Advanced-Stage Prostate Cancer

This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited other parts of the body (oligometastatic). Relugolix is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of testosterone (a male hormone) produced by the body. It may stop the growth of cancer cells that need testosterone to grow. Radiation therapy uses high-energy x rays or protons to kill tumor cells. The addition of relugolix to the radiation may reduce the chance of oligometastatic prostate cancer spreading further.

Recruiting

0 awards

Phase 2

More about Deric C. Savior

Clinical Trial Related

11 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 6 Active Clinical Trials

Treatments Deric C. Savior has experience with

  • Carboplatin
  • Paclitaxel
  • Pembrolizumab
  • Cisplatin
  • Biospecimen Collection
  • Crizotinib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Deric C. Savior specialize in?

Is Deric C. Savior currently recruiting for clinical trials?

Are there any treatments that Deric C. Savior has studied deeply?

What is the best way to schedule an appointment with Deric C. Savior?

What is the office address of Deric C. Savior?

Is there any support for travel costs?